Table 3. Results of cis-hydroxy praziquantel (CPZQ) in the tested matrices in the course of the experiment.
| Day | Water (μg/l) |
Plasma (μg/l) |
Hepatopancreas (μg/kg) |
Kidney (μg/kg) |
Muscle (μg/kg) |
Gill (μg/kg) |
Skin (μg/kg) |
| 0 | < 0.029*g | < 1.2*b | < 0.82*c | < 0.99*b | < 0.77*b | < 1.09*b | < 0.83*d |
| 1 | 3.3 ± 0.3 (3.4)de |
55.2 ± 25.3 (57.8)a |
117.9 ± 49.2 (119.0)a |
51.4 ± 17.5 (53.6)a |
24.3 ± 11.2 (18.1)a |
139.6 ± 63.5 (154.0)a |
23.5 ± 7.6 (26.7)ab |
| 2 | 4.2 ± 0.7 (4.1)cd |
41.1 ± 8.2 (42.2)a |
72.8 ± 26.4 (68.8)b |
41.2 ± 7.2 (38.5)a |
19.9 ± 5.8 (20.7)a |
133.8 ± 45.3 (142.0)a |
17.9 ± 4.8 (17.9)bc |
| 3 | 7.4 ± 0.8 (7.8)b |
45.2 ± 8.7 (43.5)a |
73.8 ± 16.7 (77.8)b |
47.3 ± 10.4 (45.5)a |
18.2 ± 4.9 (18.7)a |
168.9 ± 42.9 (167.0)a |
15.6 ± 2.1 (16.4)c |
| 4 | 10.0 ± 0.9 (10.4)a |
40.1 ± 6.3 (43.1)a |
88.8 ± 20.1 (95.7)ab |
27.7 ± 4.6 (26.3)a |
19.6 ± 7.7 (17.2)a |
142.3 ± 33.8 (136.0)a |
27.4 ± 5.6 (24.3)a |
| 10 | 52 ± 1.0 (5.2)c |
< 1.2*b | 8.0 ± 1.8 (7.6)c |
< 0.99*b | 1.9 ± 0.1 (1.9)b† |
< 1.09*b | < 0.83*d |
| 16 | 1.8 ± 0.2 (1.7)f |
< 1.2*b | 5.9 ± 1.0 (6.1)c |
< 0.99*b | < 0.77*b | < 1.09*b | < 0.83*d |
| 23 | 1.1 ± 0.1 (1.1)fg |
< 1.2*b | 2.0 ± 0.3 (1.8)c† |
< 0.99*b | < 0.77*b | < 1.09*b | < 0.83*d |
| 30 | 0.8 ± 0.3 (0.6)fg |
< 1.2*b | < 0.82*c | < 0.99*b | < 0.77*b | < 1.09*b | < 0.83*d |
a–gStatistically significant differences in the concentrations between the sampling days are indicated by different alphabetic superscript letters (P < 0.05); Data are presented as the mean ± standard deviation; the median value is given in the brackets; *Results were below the limit of detection, half of this particular limit of detection was used for the statistical analysis; †Descriptive characteristics were calculated only from the positive samples